The Potential Benefit of Oral Simethicone in Improving Colonic Visualization and Polyp Detection in Routine
Colonoscopy Screenings - Bayhealth Hospital
Phi Tran, OMS-III1; Loukya Kanakamedala, OMS-IV; Bhavin Dave, MD3
1,2 Philadelphia College of Osteopathic Medicine 3 Bayhealth Hospital

Abstract

Methods and Materials

Colon cancer is the second leading cause of cancer deaths in the United States
among men and women. Chances of occurrence of an interval cancer is 2-6%,
especially in the right colon despite a negative colonoscopy Some of the standard
bowel preps used create a frothy or “bubbly” appearance within the colon. The overall
purpose of this study is to improve quality of bowel prep and in turn increase polyp
detection with the use of Simethicone (or Gas-X). Our study has a secondary
evaluation of reducing post prep side effects (bloating, nausea, vomiting, stomach
discomfort/pain). This will be a randomized, single-blinded study comparing a splitdose bowel prep with and without the use of oral simethicone in patients undergoing
routine colonoscopy screenings. Patients in the Simethicone group took one dose of
Simethicone 30 minutes after standard bowel prep. Preliminary results have showed
that 57% (n=7) of the control group presented with froth during colonoscopy, whereas
100% (n=5) of the Simethicone group presented with no froth as well as reporting
decreased side effects of bowel prep. However, the research in ongoing and more
participants are needed to create statistically significant results. However, the initial
data has been promising to show that Simethicone may indeed be beneficial in
increasing polyp visualization and reducing the side effects associated with bowel
prep.

This will be a randomized, single-blinded study comparing a split-dose bowel prep with
and without the use of oral simethicone in patients undergoing routine colonoscopy screenings.
On the day before their procedure, they will be informed to drink their first 5.4-oz bottle at 6 pm the
day before their procedure with 40 oz of clear liquids and their second 5.4 oz bottle 5 hours
before the morning of their colonoscopy with 24 oz of clear liquids. Patients in the experimental
group will take their given dose of simethicone (Gas-X) approximately 30 minutes after the
completion of their second bottle in the prep.
The colonoscopies to be performed will be split evenly and randomly between two
attending physicians (Dr. Bhavin Dave, MD and Dr. Rahul Singh, MD). During the colonoscopy, the
following will be recorded: total procedure time, withdrawal time, mucosal findings, polyp number,
location, size, morphology and method of excision. Evaluation of polyps and frothy appearance to
colonic segments will be evaluated upon withdrawal of the scope. Photographs will be taken at the
cecum, right, transverse, and left colon. Each physician will also evaluate the quality of prep using
the Boston Bowel Preparation Scale (Matro et al., 2012). A score of 7 or more would indicate
absent or minimal bubbles with no impaired view and no flushing needed to see a 5 mm polyp. A
score of 4-6 would indicate moderately impaired view that requires flushing, and the physician
could potentially miss a polyp >5mm. A score of less than 3 indicates severely impaired view that
requires flushing, and the physician could potentially miss a polyp >10mm. Example images of
Boston Bowel Prep scoring is shown below.
It is important to note that the bubble grading criteria to be used in this study is similar
to
prior studies evaluating efficacy of bowel prep with Gas-x. This will allow for a
standardized method of prep evaluation between different studies. This study differs from others in
that simethicone is utilized after completion of the bowel prep compared to mixing simethicone
into the prep provided to the patient. It is proposed this will increase the effects of simethicone
and develop a cleaner prep overall.

Introduction
Colon cancer is the second leading cause of cancer deaths in the United
States among men and women. Many of these cancers can be prevented through
regular colonoscopy screening. However, the bowel preps used prior to the screening
procedure create a frothy or “bubbly” appearance within the colon. Physicians have
tried to overcome this with the flushing of water or using simethicone in the water
cannister during the procedure, but they have provided minimal efficacy and
simethicone damages the colonoscope. As a result, physicians have a difficult time
viewing the colonic mucosa and thoroughly inspecting the colon for polyps. There is
between a 2-6% chance of interval cancer despite negative colonoscopy. Interval
cancer could be due to several possible reasons, including biological variation in
tumor growth rates, technical limitations and suboptimal examination techniques
This study aims to objectively determine if the use of simethicone (Gas X) taken
orally after taking the bowel prep has 2 advantages: improving quality of bowel prep,
and in turn, allowing better polyp visualization, as well as also reducing the side
effects associated with bowel prep.
The unique aspect of the study is the use Simethicone (aka Gas-x) to reduce
the froth within the colon. Very few studies have evaluated ways of using
Simethicone during colonoscopies. Simethicone is an over-the-counter drug that
treats symptoms of gas by changing the surface tension of gas bubbles in the
stomach and intestines. One prior study has found some benefit in mixing liquid
simethicone within the bowel prep; however, we propose that the medication will be
more effective following the completion of the prep and reduce post prep complaints
of bloating and stomach discomfort at the same time.

Results
The control group (n=7) showed that 57% of the subjects presented with froth whereas
the remainder presented with little froth. Of the four subjects with froth, two had Boston
Score between 4-6 in all areas and two had Boston Score between 4-6 only in the right
colon. The experimental group (n=5) showed 100% with no froth during colonoscopy. One
patient was removed due to very poor prep that allowed for minimal visualization of the
colon.
The average withdrawal time in the control group was 11.14 minutes and the average
Boston Bowel Prep score was 5.57. Findings in the patients with froth included
diverticulosis and rectal adenomas. The average withdrawal time in the experimental group
was 13.8 minutes and the average Boston Bowel Prep score was 6.6. Only one patient (the
Simethicone group) had a colonoscopy that showed no abnormalities.
Post-procedure results showed that 42% of the control group complained of bloating,
nausea, and mild discomfort. No participant in the experimental group complained of postprocedure symptoms expressed by the control group.

Discussion
The initial data shows that all the patients in the experimental group (n=5) have
experienced no froth on their colonoscopies, whereas 57% of the control group (n=7)
presented with froth. It is important to note that we do have patients in the control group
who are presenting with minimal to no froth during their colonoscopy. However, no patient
in either group presented with a Boston Bowel prep score less than three. All patients with
froth had at least some colonic bubbles in their right colon at the very minimum. The
reasoning for this is still unclear. However, it should be noted that most interval cancers
that occur despite negative colonoscopy do occur in the right colon.
The average Boston Bowel Prep score between the two groups is an expected
finding. Simethicone may play a role in improving quality of prep based of the higher
Boston Bowel Prep score when compared with the control. However, the numbers are not
currently statistically significant and further participants are required.
Based on the initial data, more questions could be proposed. The patients in this
study used standard bowel preps and are having minimal froth even in the absence of
Simethicone. Other studies have claimed that froth due to bowel prep has made it difficult
to visualize the colon. We will further investigate which bowel preps were used in those
studies. Other possible explanations for the lack of froth in control groups could be due to a
Hawthorne bias, as the patients are aware they are being studied based on their
adherence to bowel prep.

Conclusions
Preliminary results show that more participants are needed to accurately compare the
control and experimental group. Based on current results, simethicone does seem to
provide some assistance in colonic visualization and overall improvement in patient
symptoms following colonoscopy. Additionally, the use of simethicone has shown improved
symptoms in the setting of bowel prep for colonoscopy. However, this is not yet statistically
significant and requires longer continuation of study.
Carolina Clavera Catalan, et al. 2019.
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